Newsroom 2014
Everything BrainStorm published in 2014.
Latest from BrainStorm
BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will release the final results from its phase 2a clinical trial of NurOwn™ in amytrophic lateral sclerosis (ALS) and hold a conference call and webcast to discuss the
BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office
NEW YORK & PETACH TIKVAH, Israel, Dec. 15, 2014 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant of
BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three and nine months ending September 30, 2014.
BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report third quarter 2014 financial results on Thursday, November 13, 2014. The Company will issue a press release before the market opens and wi
FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic lateral scle
BrainStorm Reports Last Patient Visit in Phase 2a ALS Study
BrainStorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn™ in Amyotrophic Lateral Sclerosis (ALS), conducted at the Hadas
No press releases match that search. Try a shorter phrase, or clear the field to see the full list.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.